Gast ::
| Hauptseite > Publikationsdatenbank > Isoflurane in (Super-) Refractory Status Epilepticus: A Multicenter Evaluation > print |
| Hauptseite > Publikationsdatenbank > Isoflurane in (Super-) Refractory Status Epilepticus: A Multicenter Evaluation > print |
| 001 | 904385 | ||
| 005 | 20220224125202.0 | ||
| 024 | 7 | _ | |a 10.1007/s12028-021-01250-z |2 doi |
| 024 | 7 | _ | |a 1541-6933 |2 ISSN |
| 024 | 7 | _ | |a 1556-0961 |2 ISSN |
| 024 | 7 | _ | |a 2128/30299 |2 Handle |
| 024 | 7 | _ | |a altmetric:121038917 |2 altmetric |
| 024 | 7 | _ | |a pmid:34286464 |2 pmid |
| 024 | 7 | _ | |a WOS:000677824300005 |2 WOS |
| 037 | _ | _ | |a FZJ-2021-05955 |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Stetefeld, Henning R. |0 P:(DE-HGF)0 |b 0 |
| 245 | _ | _ | |a Isoflurane in (Super-) Refractory Status Epilepticus: A Multicenter Evaluation |
| 260 | _ | _ | |a New York, NY |c 2021 |b Springer |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1642427343_24384 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 520 | _ | _ | |a AbstractBackground: We aimed to determine the association between seizure termination and side effects of isoflurane forthe treatment of refractory status epilepticus (RSE) and super-refractory status epilepticus (SRSE) in neurointensivecare units (neuro-ICUs).Methods: This was a multicenter retrospective study of patients with RSE/SRSE treated with isoflurane for statusepilepticus termination admitted to the neuro-ICUs of nine German university centers during 2011–2018.Results: We identified 45 patients who received isoflurane for the treatment of RSE/SRSE. During isoflurane treat-ment, electroencephalograms showed no epileptiform discharges in 33 of 41 (80%) patients, and burst suppressionpattern was achieved in 29 of 41 patients (71%). RSE/SRSE was finally terminated after treatment with isoflurane in 23of 45 patients (51%) for the entire group and in 13 of 45 patients (29%) without additional therapy. Lengths of stay inthe hospital and in the neuro-ICU were significantly extended in cases of ongoing status epilepticus under isofluranetreatment (p = 0.01 for length of stay in the hospital, p = 0.049 for length in the neuro-ICU). During isoflurane treat-ment, side effects were reported in 40 of 45 patients (89%) and mainly included hypotension (n = 40, 89%) and/orinfection (n = 20, 44%). Whether side effects occurred did not affect the outcome at discharge. Of 22 patients withfollow-up magnetic resonance imaging, 2 patients (9%) showed progressive magnetic resonance imaging alterationsthat were considered to be potentially associated with RSE/SRSE itself or with isoflurane therapy.Conclusions: Isoflurane was associated with a good effect in stopping RSE/SRSE. Nevertheless, establishing remis-sion remained difficult. Side effects were common but without effect on the outcome at discharge.Keywords: Status epilepticus, Isoflurane, Epilepsy |
| 536 | _ | _ | |a 5252 - Brain Dysfunction and Plasticity (POF4-525) |0 G:(DE-HGF)POF4-5252 |c POF4-525 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, Journals: juser.fz-juelich.de |
| 700 | 1 | _ | |a Schaal, Alexander |0 P:(DE-HGF)0 |b 1 |
| 700 | 1 | _ | |a Scheibe, Franziska |0 P:(DE-HGF)0 |b 2 |
| 700 | 1 | _ | |a Nichtweiß, Julia |0 P:(DE-HGF)0 |b 3 |
| 700 | 1 | _ | |a Lehmann, Felix |0 P:(DE-HGF)0 |b 4 |
| 700 | 1 | _ | |a Müller, Marcus |0 P:(DE-HGF)0 |b 5 |
| 700 | 1 | _ | |a Gerner, Stefan T. |0 P:(DE-HGF)0 |b 6 |
| 700 | 1 | _ | |a Huttner, Hagen B. |0 P:(DE-HGF)0 |b 7 |
| 700 | 1 | _ | |a Luger, Sebastian |0 P:(DE-HGF)0 |b 8 |
| 700 | 1 | _ | |a Fuhrer, Hannah |0 P:(DE-HGF)0 |b 9 |
| 700 | 1 | _ | |a Bösel, Julian |0 P:(DE-HGF)0 |b 10 |
| 700 | 1 | _ | |a Schönenberger, Silvia |0 P:(DE-HGF)0 |b 11 |
| 700 | 1 | _ | |a Dimitriadis, Konstantinos |0 P:(DE-HGF)0 |b 12 |
| 700 | 1 | _ | |a Neumann, Bernhard |0 P:(DE-HGF)0 |b 13 |
| 700 | 1 | _ | |a Fuchs, Kornelius |0 P:(DE-HGF)0 |b 14 |
| 700 | 1 | _ | |a Fink, Gereon R. |0 P:(DE-Juel1)131720 |b 15 |u fzj |
| 700 | 1 | _ | |a Malter, Michael P. |0 0000-0003-2535-4553 |b 16 |e Corresponding author |
| 773 | _ | _ | |a 10.1007/s12028-021-01250-z |g Vol. 35, no. 3, p. 631 - 639 |0 PERI:(DE-600)2176033-0 |n 3 |p 631 - 639 |t Neurocritical care |v 35 |y 2021 |x 1541-6933 |
| 856 | 4 | _ | |u https://juser.fz-juelich.de/record/904385/files/Stetefeld2021_Article_IsofluraneInSuper-RefractorySt.pdf |y OpenAccess |
| 909 | C | O | |o oai:juser.fz-juelich.de:904385 |p openaire |p open_access |p VDB |p driver |p dnbdelivery |
| 910 | 1 | _ | |a External Institute |0 I:(DE-HGF)0 |k Extern |b 5 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 15 |6 P:(DE-Juel1)131720 |
| 913 | 1 | _ | |a DE-HGF |b Key Technologies |l Natural, Artificial and Cognitive Information Processing |1 G:(DE-HGF)POF4-520 |0 G:(DE-HGF)POF4-525 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-500 |4 G:(DE-HGF)POF |v Decoding Brain Organization and Dysfunction |9 G:(DE-HGF)POF4-5252 |x 0 |
| 914 | 1 | _ | |y 2021 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2021-01-31 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2021-01-31 |
| 915 | _ | _ | |a Creative Commons Attribution CC BY 4.0 |0 LIC:(DE-HGF)CCBY4 |2 HGFVOC |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |d 2021-01-31 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b NEUROCRIT CARE : 2019 |d 2021-01-31 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2021-01-31 |
| 915 | _ | _ | |a DEAL Springer |0 StatID:(DE-HGF)3002 |2 StatID |d 2021-01-31 |w ger |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2021-01-31 |
| 915 | _ | _ | |a IF < 5 |0 StatID:(DE-HGF)9900 |2 StatID |d 2021-01-31 |
| 915 | _ | _ | |a OpenAccess |0 StatID:(DE-HGF)0510 |2 StatID |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |d 2021-01-31 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2021-01-31 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |d 2021-01-31 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2021-01-31 |
| 920 | 1 | _ | |0 I:(DE-Juel1)INM-3-20090406 |k INM-3 |l Kognitive Neurowissenschaften |x 0 |
| 980 | 1 | _ | |a FullTexts |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a UNRESTRICTED |
| 980 | _ | _ | |a I:(DE-Juel1)INM-3-20090406 |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|